度洛西汀联合丁螺环酮治疗躯体形式障碍患者的疗效及安全性观察

Clinical efficacy and safety of Duloxetine combined with Buspirone in treatment of the somatoform disorders

目的:观察度洛西汀联合丁螺环酮治疗躯体形式障碍患者的疗效及安全性。方法:将71例躯体形式障碍患者随机分为研究组和对照组。研究组患者36例,给予度洛西汀联合丁螺环酮治疗;对照组患者35例,单独给予度洛西汀治疗。两组患者的疗程均为6周。治疗前及治疗后第2、4、6周,采用汉密尔顿焦虑量表(HAMA)和临床疗效总评量表(CGI)对两组患者的疗效进行评定和比较。结果:治疗后2、4、6周与治疗前相比较,两组患者的评分均明显降低(P<0.01);治疗后第4、6周,研究组患者的评分明显低于对照组(P<0.05);CGI评分显示:研究组患者自第2周开始出现明显疗效,且第4、6周评分优于对照组(P<0.05)。结论:度洛西汀联合丁螺环酮治疗躯体形式障碍患者的疗效优于单用度洛西汀治疗,且未增加不良反应。

Objective:To discuss efficacy and safety of Duloxetine combined with Buspirone in treatment of patients with som-atoform disorders. Methods:71 patients with somatoform disorders were randomly divided into research group(Duloxetine combined with Buspirone group)(n=36)and control group(Duloxetine group)(n= 35),and were treated for 6 weeks. The efficacies of the two groups were evaluated and compared with Hamilton anxiety scale(HAMA)and clinical global impression(CGI)before and 2,4 and 6 weeks after the treatment. Results:The scores of HAMA of the two groups decreased significantly 2,4 and 6 weeks after the treatment(P<0. 01). Compared with the control group,the scores of HAMA decreased more significantly in the research group 4 and 6 weeks after the treatment(P<0. 05). The scores of CGI showed that:the research group received obvious efficacy 2 weeks after the treatment and the scores decreased obviously than control groups in 4th and 6th weeks(P<0. 05). Conclusions:Duloxetine combined with Buspirone is more effective in the treatment of the patients with somatoform disorder than duloxetine only.